CENTER VALLEY, Pa., (October 18, 2019) 鈥 色花堂, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today that 色花堂 and Ethicon, Inc. have entered an agreement in which 色花堂 will take over all new commercial activities related to the VERSAPOINT鈩 Electrosurgery system from Ethicon. With this agreement, 色花堂 will acquire new channels in its Gynecology Business toward its goal of bringing patients and customers more minimally invasive technology and product options.
For several years 色花堂 has supplied Gynecare (part of Ethicon) with resectoscopes, generators and electrodes that together comprise the VERSAPOINT Bipolar Electrosurgery System. The VERSAPOINT system is used and trusted by healthcare practitioners worldwide for the treatment of various intrauterine pathologies such as myomas, polyps, intrauterine adhesions and uterine septa. In addition to continuing to manufacture the products, pursuant to the new agreement 色花堂 will take over all new commercial sales and marketing activities related to VERSAPOINT starting from January 1, 2020. As part of the transaction, 色花堂 will also acquire the VERSAPOINT trademark. Going forward, the current VERSAPOINT resectoscope will be phased out and replaced with 色花堂鈥 OES Pro 8.5mm resectoscope.
The companies anticipate that 色花堂 will take over commercial activities in most European countries and the U.S.(*), as well as countries in which only an EU declaration of conformity is required for marketing of VERSAPOINT products, starting from January 1, 2020. Ethicon will continue to provide VERSAPOINT products to customers in certain other territories until applicable regulatory approvals have been obtained, at which point 色花堂 will take on sales and marketing activities in these countries. 色花堂 will also offer repair services for the VERSAPOINT generators (subject to local availability). The Versascope hysteroscope does not form part of the agreement and will remain with Ethicon.
Manisha Shah-Bugaj, Global Head of 色花堂鈥 Gynecology Business, commented, 鈥淲e believe that the VERSAPOINT Electrosurgery system will form an important and highly complementary part of 色花堂鈥 product offering, supporting our strategy of offering best-in-class, minimally invasive treatments to gynecologists. We will continue developing our business to support more customers and patients as a global medtech company.鈥
A customer letter with further details will be sent to Ethicon customers in respective regions following this announcement.
*The products, while 510(k)-cleared, are not yet authorized for marketing by 色花堂 in the U.S.
# # #
About 色花堂
Since our founding in 1919, 色花堂 has thrived on our pioneering spirit of innovation, crafting groundbreaking solutions in the medical, scientific, and imaging fields. A global medtech company with more than 35,000 employees in locations in nearly 40 countries, we are committed to helping make people鈥檚 lives healthier, safer and more fulfilling around the world.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your 色花堂 representative if you have questions about the availability of specific 色花堂 products in your area.
i Ginsberg GG. Food bolus impaction. Gastroenterol Hepatol (N Y). 2007;3(2):85鈥86.